Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tafenoquine

- PMLiVE

GSK to reverse ‘no KOLs’ policy, admitting it has hit marketing

Company seeking to revive lacklustre marketing performance

- PMLiVE

Boehringer’s Corsico to be new GSK drug dev leader

Research and drug development will be split into separate divisions

- PMLiVE

FDA rejects GSK’s Nucala for COPD

Says evidence that Nucala was effective in preventing COPD exacerbations was insufficient

AstraZeneca AZ

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Its combo missed two of the main endpoints of the study

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

- PMLiVE

GSK: we won’t be splitting up any time soon

Walmsley scotches rumours of a consumer health spin-off

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

The latest from pharma, biotech and healthcare

- PMLiVE

GSK sells eczema and psoriasis drug to Dermavant for £250m

The British group is selling off assets outside core therapy areas to boost R&D

- PMLiVE

Weekly industry appointments

GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board

- PMLiVE

GSK’s vaccines president Debruyne heads for the exit

Roger Connor to take on the role in latest shake up

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links